Guido Fallani

Guido Fallani

Auto-generated profile, based on publicly available information

Guido Fallani

Department of Medical and Surgical Sciences University of Bologna Bologna Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Matteo RavaioliMatteo Ravaioli
Matteo Ravaioli
VPVanessa De Pace
Vanessa De Pace
AAAndrea Angeletti
Andrea Angeletti
GCGiorgia Comai
Giorgia Comai
FVFrancesco Vasuri
Francesco Vasuri
Gaetano La MannaGaetano La Manna
Gaetano La Manna
With the aim to explore innovative tools for organ preservation, especially in marginal organs, we hereby describe a clinical trial of ex-vivo hypothermic oxygenated perfusion (HOPE) in the field of liver (LT) and kidney transplantation (KT) from Extended Criteria Donors (ECD) after brain death. A matched-case analysis of donor and recipient variables was developed: 10 HOPE-ECD livers and kidneys (HOPE-L and HOPE-K) were matched 1:3 with livers and kidneys preserved with static cold storage (SCS-L and SCS-K). HOPE and SCS groups resulted with similar basal characteristics, both for recipients and donors. Cumulative liver and kidney graft dysfunction were 10% (HOPE L-K) vs. 31.7%, in SCS group (p = 0.05). Primary non-function was 3.3% for SCS-L vs. 0% for HOPE-L. No primary non-function was reported in HOPE-K and SCS-K. Median peak aspartate aminotransferase within 7-days post-LT was significantly higher in SCS-L when compared to HOPE-L (637 vs.344 U/L, p = 0.007). Graft survival at 1-year post-transplant was 93.3% for SCS-L vs. 100% of HOPE-L and 90% for SCS-K vs. 100% of HOPE-K. Clinical outcomes support our hypothesis of machine perfusion being a safe and effective system to reduce ischemic preservation injuries in KT and in LT.

2 April 2019 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
MSMatteo Serenari
Matteo Serenari
ACAlessandro Cucchetti
Alessandro Cucchetti
PRPaolo Maria Russo
Paolo Maria Russo
GFGuido Fallani
Guido Fallani
KMKatia Mattarozzi
Katia Mattarozzi
MCMatteo Cescon
Matteo Cescon

7 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Matteo RavaioliMatteo Ravaioli
Matteo Ravaioli
FOFederica Odaldi
Federica Odaldi
ACAlessandro Cucchetti
Alessandro Cucchetti
FTFranco Trevisani
Franco Trevisani
FPFabio Piscaglia
Fabio Piscaglia
APAntonio Daniele Pinna
Antonio Daniele Pinna
The objective of the study is to evaluate 10 years of down-staging strategy for liver transplantation (LT) with a median follow-up of 5 years. Data on long-term results are poor and less information is available for hepatocellular carcinoma (HCC) non-responder patients or those ineligible for down-staging. The outcome of 308 HCC candidates and the long-term results of 231 LTs for HCC performed between 2003 and 2013 were analyzed. HCCs were divided according to tumor stage and response to therapy: 145 patients were T2 (metering Milan Criteria, MC), 43 were T3 successfully down-staged to T2 (Down-Achieved), 20 were T3 not fully down-staged to T2 (Down-not Achieved), and 23 patients were T3 not receiving down-staging treatments (No-Down). The average treatment effect (ATE) of LT for T3 tumors was estimated using the outcome of 535 T3 patients undergoing non-LT therapies, using inverse probability weighting regression adjustment. The 24-month drop-out rate during waiting time was significantly higher in the down-staging groups: 27.6% vs. 9.2%, p < 0.005. After LT, the tumor recurrence rate was significantly different: MC 7.6%, Down-Achieved 20.9%, Down-not Achieved 31.6%, and No-Down 30.4% (p < 0.001). The survival rates at 5 years were: 63% in Down-Achieved, 62% in Down-not Achieved, 63% in No-Down, and 77% in MC (p = n.s.). The only variable related to a better outcome was the effective down-staging to T2 at the histological evaluation of the explanted liver: recurrence rate = 7.8% vs. 26% (p < 0.001) and 5-year patient survival = 76% vs. 67% (p < 0.05). The ATE estimation showed that the mean survival of T3-LT candidates was significantly better than that of T3 patients ineligible for LT [83.3 vs 39.2 months (+44.6 months); p < 0.001]. Long term outcome of T3 down-staged candidates was poorer than that of MC candidates, particularly for cases not achieving down-staging. However, their survival outcome was significantly better than that achieved with non-transplant therapies.

19 March 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
Matteo RavaioliMatteo Ravaioli
Matteo Ravaioli
LMLorenzo Maroni
Lorenzo Maroni
AAAndrea Angeletti
Andrea Angeletti
GFGuido Fallani
Guido Fallani
VPVanessa De Pace
Vanessa De Pace
Gaetano La MannaGaetano La Manna
Gaetano La Manna
Background: Extended criteria donors (ECD) are widely utilized due to organ shortage, but they may increase the risk of graft dysfunction and poorer outcomes. Hypothermic oxygenated perfusion (HOPE) is a recent organ preservation strategy for marginal kidney and liver grafts, allowing a redirect from anaerobic metabolism to aerobic metabolism under hypothermic conditions and protecting grafts from oxidative species–related damage. These mechanisms may improve graft function and survival. Objective: With this study, we will evaluate the benefit of end-ischemic HOPE on ECD grafts for livers and kidneys as compared to static cold storage (SCS). The aim of the study is to demonstrate the ability of HOPE to improve graft function and postoperative outcomes of ECD kidney and liver recipients. Methods: This is an open-label, single-center randomized clinical trial with the aim of comparing HOPE with SCS in ECD kidney and liver transplantation. In the study protocol, which has been approved by the ethics committee, 220 patients (110 liver recipients and 110 kidney recipients) will be enrolled. Livers and kidneys assigned to the HOPE group undergo machine perfusion with cold Belzer solution (4-10°C) and continuous oxygenation (partial pressure of oxygen of 500-600 mm Hg). In the control group, livers and kidneys undergoing SCS are steeped in Celsior solution and stored on ice. Using the same perfusion machine for both liver and kidney grafts, organs are perfused from the start of the back-table procedure until implantation, without increasing the cold ischemia time. For each group, we will evaluate clinical outcomes, graft function tests, histologic findings, perfusate, and the number of allocated organs. Publication of the results is expected to begin in 2021. Results: Dynamic preservation methods for organs from high-risk donors should improve graft dysfunction after transplantation. To date, we have recruited 108 participants. The study is ongoing, and recruitment of participants will continue until January 2020. Conclusions: The proposed preservation method should improve ECD graft function and consequently the postoperative patient outcomes. Trial Registration: ClinicalTrials.gov NCT03837197; https://clinicaltrials.gov/ct2/show/NCT03837197 ; Archived by WebCite® at http://www.webcitation.org/76fSutT3R International Registered Report Identifier (IRRID): DERR1-10.2196/13922

1 September 2018 in Surgery
Verified
Journal Article
Closed access
Matteo RavaioliMatteo Ravaioli
Matteo Ravaioli
GFGuido Fallani
Guido Fallani
MCMatteo Cescon
Matteo Cescon
EPEnrico Prosperi
Enrico Prosperi
VPVanessa De Pace
Vanessa De Pace
IGIngrid Garajová
Ingrid Garajová

1 March 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
Matteo RavaioliMatteo Ravaioli
Matteo Ravaioli
QLQuirino Lai
Quirino Lai
MSMaurizio Sessa
Maurizio Sessa
DGDavide Ghinolfi
Davide Ghinolfi
GFGuido Fallani
Guido Fallani
PSPaolo De Simone
Paolo De Simone